Deals mask CytomX’s fundamental problem
Another disappointment raises fresh doubts about CytomX’s extensively partnered masked therapeutics.
Pfizer takes multiple shots on goal
The company’s post-Seagen ADC portfolio features overlapping targets with differing payloads.
Deal analysis part one – the bad
A look at big oncology deals since 2016 suggests that there have been more duds than successes.
The complex web of PARP inhibitor development
GSK’s Zejula win is the latest chapter in a long and convoluted history of PARP inhibition.
